• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma.

作者信息

Alkhateeb Hassan B, Mohty Razan, Greipp Patricia, Bansal Radhika, Hathcock Matthew, Rosenthal Allison, Murthy Hemant, Kharfan-Dabaja Mohamed, Bisneto Villasboas Jose C, Bennani Nora, Ansell Stephen M, Patnaik Mrinal M, Litzow Mark R, He Rong, Chen Dong, Al-Kali Aref, Kenderian Saad S, Lin Yi, Shah Mithun Vinod

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.

出版信息

Blood Cancer J. 2022 Jul 26;12(7):113. doi: 10.1038/s41408-022-00707-4.

DOI:10.1038/s41408-022-00707-4
PMID:35882844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9325766/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/9325766/e11e8560987f/41408_2022_707_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/9325766/c53fd9590290/41408_2022_707_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/9325766/e11e8560987f/41408_2022_707_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/9325766/c53fd9590290/41408_2022_707_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/9325766/e11e8560987f/41408_2022_707_Fig2_HTML.jpg

相似文献

1
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma.嵌合抗原受体T细胞疗法治疗非霍奇金淋巴瘤后发生的治疗相关髓系肿瘤
Blood Cancer J. 2022 Jul 26;12(7):113. doi: 10.1038/s41408-022-00707-4.
2
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.恶病质是接受嵌合抗原受体T细胞疗法治疗B细胞非霍奇金淋巴瘤患者出现不良临床和功能结局的一个危险因素。
Br J Haematol. 2022 Apr;197(1):71-75. doi: 10.1111/bjh.18054. Epub 2022 Feb 9.
3
Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.推动CAR-T疗法迈向终点：将放射治疗融入嵌合抗原受体T细胞治疗方案以改善复发/难治性弥漫性大B细胞淋巴瘤患者的预后
Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1152-1158. doi: 10.1016/j.ijrobp.2023.03.076. Epub 2024 Mar 14.
4
A ray of hope in a dire situation: Radiotherapy for progression after chimeric antigen receptor T-cell therapy.绝境中的一线希望：嵌合抗原受体T细胞疗法进展后的放射治疗
Br J Haematol. 2020 Jul;190(1):18-19. doi: 10.1111/bjh.16562. Epub 2020 Mar 4.
5
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.异基因造血细胞移植后嵌合抗原受体T细胞疗法治疗复发/难治性B细胞非霍奇金淋巴瘤的安全性和可行性
Leukemia. 2019 Oct;33(10):2540-2544. doi: 10.1038/s41375-019-0476-y. Epub 2019 May 21.
6
Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.异基因造血干细胞移植和嵌合抗原受体（CAR）T 细胞治疗非霍奇金淋巴瘤。
Hematol Oncol Clin North Am. 2019 Aug;33(4):687-705. doi: 10.1016/j.hoc.2019.03.005. Epub 2019 May 10.
7
Perceived Cognitive Changes following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?嵌合抗原受体T细胞疗法治疗淋巴瘤后感知到的认知变化：感知预期？
Transplant Cell Ther. 2023 Jan;29(1):64. doi: 10.1016/j.jtct.2022.09.008. Epub 2022 Sep 21.
8
Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?回应：嵌合抗原受体T细胞疗法治疗淋巴瘤后感知到的认知变化：感知预期？
Transplant Cell Ther. 2023 Jan;29(1):65. doi: 10.1016/j.jtct.2022.09.019. Epub 2022 Sep 27.
9
Redefining Non-Hodgkin Lymphoma: Using Genomic Subtypes to Improve Treatment Options.重新定义非霍奇金淋巴瘤：利用基因组亚型改善治疗方案
Hematol Oncol Clin North Am. 2019 Aug;33(4):xiii-xiv. doi: 10.1016/j.hoc.2019.04.005. Epub 2019 May 15.
10
Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.嵌合抗原受体 T 细胞疗法治疗非霍奇金淋巴瘤的最新进展。
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):751-757. doi: 10.1016/j.clml.2019.09.598. Epub 2019 Oct 2.

引用本文的文献

1
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
2
Decoding the immune microenvironment of secondary chronic myelomonocytic leukemia due to diffuse large B-cell lymphoma with CD19 CAR-T failure by single-cell RNA-sequencing.通过单细胞RNA测序解析弥漫性大B细胞淋巴瘤伴CD19嵌合抗原受体T细胞（CAR-T）治疗失败所致继发性慢性粒单核细胞白血病的免疫微环境
Chin Med J (Engl). 2025 Aug 5;138(15):1866-1881. doi: 10.1097/CM9.0000000000003690. Epub 2025 Jul 7.
3
Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?

本文引用的文献

1
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.嵌合抗原受体 T 细胞治疗患者的克隆性造血。
Blood Adv. 2021 Aug 10;5(15):2982-2986. doi: 10.1182/bloodadvances.2021004554.
2
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.接受 PARP 抑制剂治疗的患者的骨髓增生异常综合征和急性髓系白血病：随机对照试验的安全性荟萃分析和世界卫生组织药物警戒数据库的回顾性研究。
Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18.
3
CAR-T细胞治疗B细胞淋巴瘤后与长期免疫细胞相关血液毒性相关的髓系肿瘤的发生：我们应该监测是否存在预先存在的髓系突变吗？
Hemasphere. 2025 Jun 5;9(6):e70160. doi: 10.1002/hem3.70160. eCollection 2025 Jun.
4
TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.TP53 突变的髓系肿瘤：2024 年诊断、风险分层及管理更新
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):88-115. doi: 10.1002/ajh.27655. Epub 2025 Mar 11.
5
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.免疫效应细胞相关的血液毒性：机制、临床表现及管理策略。
Haematologica. 2025 Jun 1;110(6):1254-1268. doi: 10.3324/haematol.2024.286027. Epub 2025 Feb 20.
6
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities.接受嵌合抗原受体T细胞（CAR-T）治疗患者中的T细胞淋巴瘤：评估风险和因果关系
Blood. 2024 Dec 12;144(24):2473-2481. doi: 10.1182/blood.2024025828.
7
The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?嵌合抗原受体 T 细胞疗法后继发性恶性肿瘤的现状：如何预防恶性肿瘤？
Int J Mol Sci. 2024 Sep 1;25(17):9518. doi: 10.3390/ijms25179518.
8
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.嵌合抗原受体 T 细胞（CAR T）治疗后第二原发恶性肿瘤：5517 例淋巴瘤和骨髓瘤患者的系统评价和荟萃分析。
Clin Cancer Res. 2024 Oct 15;30(20):4690-4700. doi: 10.1158/1078-0432.CCR-24-1798.
9
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.淋巴瘤患者接受 CD19 靶向嵌合抗原受体 T 细胞治疗后的继发恶性肿瘤。
Transplant Cell Ther. 2024 Oct;30(10):990-1000. doi: 10.1016/j.jtct.2024.06.027. Epub 2024 Jul 6.
10
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.抗CD19嵌合抗原受体T细胞疗法治疗复发/难治性B细胞非霍奇金淋巴瘤后的晚期事件
Front Oncol. 2024 Jun 11;14:1404351. doi: 10.3389/fonc.2024.1404351. eCollection 2024.
Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
继发性和治疗相关性急性髓系白血病的遗传和基因组景观。
Genes (Basel). 2020 Jul 6;11(7):749. doi: 10.3390/genes11070749.
4
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.肽受体放射性核素治疗后神经内分泌肿瘤患者治疗相关骨髓性肿瘤的评估：系统评价。
JAMA Oncol. 2020 Jul 1;6(7):1086-1092. doi: 10.1001/jamaoncol.2020.0078.
5
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.KTE-X19 嵌合抗原受体 T 细胞疗法治疗复发或难治性套细胞淋巴瘤。
N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347.
6
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.CD19靶向嵌合抗原受体修饰T细胞治疗后的晚期事件
Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33. doi: 10.1016/j.bbmt.2019.08.003. Epub 2019 Aug 13.
7
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
8
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.淋巴瘤和浆细胞骨髓瘤自体移植后发生急性髓系白血病和骨髓增生异常综合征的风险。
Leuk Res. 2018 Nov;74:130-136. doi: 10.1016/j.leukres.2018.07.016. Epub 2018 Jul 19.
9
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
10
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.